Infection

, Volume 19, Supplement 1, pp S29–S32 | Cite as

Zentralnervöse Nebenwirkungen verschiedener antibakterieller Substanzen

  • G. Stoppe
  • E. Rüther
Nebenwirkungsprofile Bei Antibakteriell Wirksamen Chemotherapeutika
  • 29 Downloads

Zusammenfassung

Diese Übersichtsarbeit beschäftigt sich mit den zentralnervösen Nebenwirkungen verschiedener Antibiotika. Besondere Aufmerksamkeit wird dabei den neuen Chinolonderivaten, den Penicillinen und Cephalosporinen gewidmet. Wirkmechanismen werden — soweit sie bisher geklärt werden konnten — diskutiert, ebenso wie therapeutische Möglichkeiten.

Central nervous system side effects of different antibacterial agents

Summary

This review concerns central nervous system side effects of different antibacterial agents. Special attention is focussed on the new quinolone derivatives, penicillins and cephalosporins. As far as possible, mechanisms of action are discussed as well as therapeutic regimens.

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.
    Harder, S., Shah, P. M., Staib, A. H. Gyrase-Hemmstoffe: Zentralnervöse Nebenwirkungen und Hemmung der Methylxanthinelimination. Dtsch. Med. Wochenschr. 115 (1990) 270–273.Google Scholar
  2. 2.
    Mathias, B., Hopf, G., Kimbel, H.: Mehr als zehntausend Berichte über unerwünschte Arzneimittelwirkungen. Dtsch. Ärztebl. 85 (1988) B 2424.Google Scholar
  3. 3.
    Wijnands, W. J. A., Vree, T. B., van Herwaarden, C. L. A. The influence of quinolone derivatives on therophylline clearance. Br. J. Clin. Pharmacol. 22 (1986) 677.Google Scholar
  4. 4.
    Harder, S., Staib, A. H., Beer, C., Papenburg, A., Stille, W., Shah, P. M. 4-Quinolones inhibit biotransformation of caffeine. Europ. J. Clin. Pharmacol. 35 (1988) 651.Google Scholar
  5. 5.
    Stille, W. Verträglichkeit der Gyrasehemmer. Münchner Med. Wochenschr. 129 (1987) 45–46.Google Scholar
  6. 6.
    Grassi, G. G. A multicenter study in clinical efficacy of ofloxacin in respiratory and urinary tract infections. Infection 14 (1986) 300–302.Google Scholar
  7. 7.
    Zaudig, M., von Bose, M., Weber, M., Bremer, D., Zieglgänsberger, W. Psychotoxic effects of ofloxacin. Pharmacopsychiat. 22 (1989) 11–15.Google Scholar
  8. 8.
    Anastasio, G. D., Menscer, D., Little, J. M. Norfloxacin and seizures (letter). Ann. Intern. Med. 109 (1988) 169–170.Google Scholar
  9. 9.
    Simpson, K. J., Brodie, M. J. Convulsions related to enoxacin. Lancet ii (1985) 161.Google Scholar
  10. 10.
    Gleckman, R., Alvarez, S., Joubert, D. W., Matthews, S. J. Drug therapy reviews: nalidixic acid. Am. J. Hosp. Pharmacol. 36 (1979) 1071–1076.Google Scholar
  11. 11.
    Blomer, R., Bruch, K., Krauss, H., Wachek, W. Safety of ofloxacin-adverse drug reactions reported during phase II studies in Europe and in Japan. Infection 14 (1986) 332–334.Google Scholar
  12. 12.
    Nix, D. E., Schentag, J. J. The quinolones: An overview and comparative appraisal of their pharmacokinetics and pharmacodynamics. J. Clin. Pharmacol. 28 (1988) 169–178.Google Scholar
  13. 13.
    Reeves, D. S., Lacey, R. W., Mummery, R. V., Mahendra, M., Bint, A. J., Newsom, S. W. B. Treatment of acute urinary infection by norfloxacin or nalidixic acid citrate: a multicenter comparative study. J. Antimicrob. Chemother. 13, Suppl. B (1984) 99–105.Google Scholar
  14. 14.
    Lucet, J. C., Tilly, H., Lerebours, G., Gres, J. J., Piguet, H. Neurological toxicity related to pefloxacin. J. Antimicrob. Chemother. 21 (1988) 811–812.Google Scholar
  15. 15.
    Hori, S.: Effect of new quinolones on gamma-aminobutyric acid receptor binding. 25. ICAAC (Minneapolis 1985): Abstract 396.Google Scholar
  16. 16.
    Hori, S.: Inhibitory effect of quinolones on gamma-aminobutyric acid receptor binding: structure-activity relationship. 26. ICAAC (Minneapolis 1986): Abstract 438.Google Scholar
  17. 17.
    Emrich, H. M., v. Zerssen, D., Kissling, W., Möller, H. J., Windorfer, A. Effect of sodium valproate on mania. The GABA hypothesis of affective disorders. Arch. Psychiatr. Nervenkr. 229 (1980) 1–16.Google Scholar
  18. 18.
    Segev, S., Rechavy, M., Rubinstein, E.: Quinolones, theophylline, and diclofenac interactions with the CNS GABA receptor. 27th Interscience Conference of Antimicrobial Agents and Chemotherapy (New York 1987): Abstract 28.Google Scholar
  19. 19.
    Drancourt, M., Gallais, H., Raoult, D., Estrangin, E., Mallet, M. N., Demicco, P. Ofloxacin penetration into cerebrospinal fluid. J. Antimicrob. Chemother. 22 (1988) 263–265.Google Scholar
  20. 20.
    Wolff, M., Regnier, B., Daldoss, C., Nkam, M., Vachon, F. Penetration of pefloxacin into cerebrospinal fluid of patients with meningitis. Antimicrob. Agents Chemother. 26 (1984) 289–291.Google Scholar
  21. 21.
    Montay, G., Gueffon, Y., Roquet, F. Absorption, distribution, metabolic fate and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys and humans. Antimicrob. Agents Chemother. 25 (1984) 463–472.Google Scholar
  22. 22.
    Schnuch, A. Gyrase-Hemmer: zentralnervöse Nebenwirkungen (letter). Dtsch. Med. Wochenschr. 112 (1987) 569.Google Scholar
  23. 23.
    Juorio, A. V. The effects of amfonelic acid and some other central nervous stimulants on mouse striatal tyramine, dopamine and homovanillic acid. Br. J. Pharmac. 77 (1982) 511.Google Scholar
  24. 24.
    Rietbrock, N., Staib, A. H. Gyrase-Hemmer, unerwünschte zentralnervöse Nebenwirkungen. Dtsch. Med. Wochenschr. 112 (1987) 201.Google Scholar
  25. 25.
    Lhermitte, F., Signoret, J. L., Agid, Y., Laffont, F., Jouvent, R. Traitement d'un état hallucinosique avec hypersomnie diurne par l'acide oxolinique. Nouvelle Presse Médicale 7 (1987) 3936.Google Scholar
  26. 26.
    Snavely, S. S., Hodges, G. R. The neurotoxicity of antibacterial agents. Ann. Intern. Med. 101 (1984) 92–104.Google Scholar
  27. 27.
    Cohen, S. B. Psychosis resulting from penicillin hypersensitivity: report of a case and review of the literature. Am. J. Psychiat. 111 (1955) 699–702.Google Scholar
  28. 28.
    Bateman, J. C., Barberio, J. R., Grice, P., Klopp, C. T., Pierpont, H. Fatal complications of intensive antibiotic therapy in patients with neoplastic disease. Arch. Intern. Med. 90 (1952) 763–773.Google Scholar
  29. 29.
    Weinstein, L., Lerner, P. I., Chwe, W. H. Clinical and bacteriological studies of the effect of massive doses of penicillin G on infections caused by gram-negative bacilli. N. Engl. J. Med. 271 (1964) 525–533.Google Scholar
  30. 30.
    News, P. S., Wells, C. E. Cerebral toxicity associated with massive intravenous penicillin therapy. Neurology 15 (1965) 1053–1058.Google Scholar
  31. 31.
    Dobell, A. R. C., Wyant, J. D., Seamans, K. B., Gloor, P. Penicillin epilepsy: studies on the blood-brain barrier during cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 52 (1966) 469–475.Google Scholar
  32. 32.
    Oldstone, M. B. A., Nelson, E. Central nervous system manifestations of penicillin toxicity in man. Neurology 16 (1966) 693–700.Google Scholar
  33. 33.
    Bloomer, H. A., Barton, L. J., Maddock, R. K. Penicillin-induced encephalopathy in uremic patients. J. Amer. Med. Assoc. 200 (1967) 121–123.Google Scholar
  34. 34.
    Lerner, P. I., Smith, H., Weinstein, L. Penicillin neurotoxicity. Ann. NY Acad. Sci. 145 (1967) 310–318.Google Scholar
  35. 35.
    Lavy, S., Stein, H. Convulsions in septicemic patients treated by penicillin: the value of electroencephalograph examination. Arch. Surg. 100 (1970) 225–228.Google Scholar
  36. 36.
    Kurtzman, N. A., Rogers, P. W., Harter, H. R. Neurotoxic reaction to penicillin and carbenicillin. J. Amer. Med. Assoc. 214 (1970) 1320–1321.Google Scholar
  37. 37.
    Raichle, M. E., Kutt, H., Louis, S., McDowell, F. Neurotoxicity of intravenously administered penicillin G. Arch. Neurol. 25 (1971) 232–239.Google Scholar
  38. 38.
    Fossieck, B., Parker, R. H. Neurotoxicity during intravenous infusion of penicillin. A review. J. Clin. Pharmacol. 14 (1974) 504–512.Google Scholar
  39. 39.
    Beal, D. M., Hudson, B., Zaiac, M. Amoxicillin-induced psychosis (letter). Am. J. Psychiat. 143 (1986) 255–256.Google Scholar
  40. 40.
    Weihrauch, T. R., Prior, H. J., Höffler, D., Krieglstein, J. Über die Neurotoxizität von Carbenicillin. Klin. Wochenschr. 52 (1974) 842–846.Google Scholar
  41. 41.
    Gutnick, M. J., Prince, D. A. Penicillinase and the convulsant action of penicillin. Neurology 21 (1971) 759–764.Google Scholar
  42. 42.
    Sobotka, P., Safanda, J. The epileptogenic action of penicillins: structure — activity relationship. J. Mol. Med. 1 (1976) 151–159.Google Scholar
  43. 43.
    Meyer, H., Prince, D. Convulsant actions of penicillin: effects on inhibitory mechanisms. Brain Res. 53 (1973) 477–482.Google Scholar
  44. 44.
    Van Duijn, H., Schwartzkroin, P. A., Prince, D. A. Action of penicillin on ihibitory processes in the cat's cortex. Brain Res. 53 (1973) 470–476.Google Scholar
  45. 45.
    Dingledine, R., Gjerstad, L. Penicillin blocks hippocampal IPSPs, unmasking prolonged EPSPs. Brain Res. 168 (1979) 205–209.Google Scholar
  46. 46.
    Barker, J. L. GABA and glycine: Ion channel mechanisms. In:Rogawski, M. A., Barker, J. L. (eds): Neurotransmitter action in the vertebrate nervous system. Plenum Press, New York, London, 1985.Google Scholar
  47. 47.
    Antoniadis, A., Mueller, W. E., Wollert, U. Benzodiazepine receptor interactions may be involved in the neurotoxicity of various penicillin derivatives. Ann. Neurol. 8 (1980) 71–73.Google Scholar
  48. 48.
    Schwartzkroin P. A., Wyler, A. R. Mechanisms underlying epileptiform burst discharge. Ann. Neurol. 7 (1980) 95–107.Google Scholar
  49. 49.
    Ebersole, J. S., Chatt, A. B. Toward a unified theory of focal penicillin epileptogenesis: an intracortical evoked potential investigation. Epilepsia 22 (1981) 347–363.Google Scholar
  50. 50.
    Batchelor, R. C. L., Horne, G. O., Rogerson, H. L. An unusual reaction to procaine penicillin in aqueous suspension. Lancet 261 (1951) 195–198.Google Scholar
  51. 51.
    Sohval, A. R. Severe immediate constitutional reaction to penicillin. J. Amer. Med. Assoc. 151 (1953) 1430–1431.Google Scholar
  52. 52.
    Bjornberg, A., Selstam, J. Acute psychotic reaction after injection of procaine penicillin. Acta Psychol. Neurol. Scand. 35 (1960) 129–139.Google Scholar
  53. 53.
    Utley, P. M., Lucads, J. B., Billings, T. E. Acute psychotic reactions to aqueous procaine penicillin. Southern Med. J. 59 (1966) 1271–1274.Google Scholar
  54. 54.
    Menke, H. E., Pepplinkhuezen, L. Acute non-allergic reaction to aqueous procaine penicillin. Lancet ii (1974) 723–724.Google Scholar
  55. 55.
    Galpin, J. E., Chow, A. W., Yoshikawa, T. T. Pseudoanaphylactic reaction from inadvertent infusion of procain penicillin G. Ann. Intern. Med. 81 (1974) 358–359.Google Scholar
  56. 56.
    Vacek, J., Calkova, M. Psychopathologische Reaktionen nach Depot-Penicillin. Hoigné-Syndrom. Psychiat. Neurol. Med. Psychol. (Leipzig) 34 (1982) 602–609.Google Scholar
  57. 57.
    Lankin, D. L., Jewell, G. M., Grinvalsky, H. T., Fye, D. L. Psychotic-like reaction to procaine penicillin G. Ann. Emerg. Med. 12 (1983) 507–509.Google Scholar
  58. 58.
    Cummings, J. L., Barritt, C. F., Horan, M. Delusions induced by procaine penicillin: Case report and review of the syndrome. Int. J. Psychiat. Med. 16 (1986) 163–168.Google Scholar
  59. 59.
    Axelrod, M. Pulmonary embolism following injection of penicillin in oil and wax. J. Amer. Med. Assoc. 142 (1950) 802–804.Google Scholar
  60. 60.
    Dennig, H., Schwoerer, W. Akute Procainvergiftung bei Anwendung von Depot-Penicillin. Dtsch. Med. Wochenschr. 88 (1963) 532–537.Google Scholar
  61. 61.
    Hoigné, R., Krebs, A. Kombinierte anaphylaktische und embolischtoxische Reaktion durch akzidentelle intravaskuläre Injektion von Procain-Penicillin. Schweiz. Med. Wochenschr. 94 (1964) 610–614.Google Scholar
  62. 62.
    Hoigné, R. Syndrome der Arzneimittel-Sensibilierung. Dtsch. Med. Wochenschr. 86 (1971) 841–851.Google Scholar
  63. 63.
    Turner, W. M. Lidocaine and psychotic reactions. Ann. Intern. Med. 97 (1982) 149–150.Google Scholar
  64. 64.
    Strauss, W., Risser, A., Jones, M. W. Fear responses in patients with epilepsy. Arch. Neurol. 39 (1982) 626–630.Google Scholar
  65. 65.
    Yoshioka, H., Nambu, H., Fujita, M., Uehara, H. Convulsion following intrathecal cephaloridine. Infection 3 (1975) 123–124.Google Scholar
  66. 66.
    Bechtel, T. P., Slaughter, R. L., Moore, T. D. Seizures associated with high cerebrospinal fluid concentrations of cefazolin. Am. J. Hosp. Pharm. 37 (1980) 271–273.Google Scholar
  67. 67.
    Weinstein, L. Antimicrobial agents: penicillins and cephalosporins. In:Goodman, L. S., Gilman, A. (eds.): The pharmacological basis of therapies. 5th Ed.. Mac Millan Publishing Co. Inc., New York 1975, pp. 1130–1146.Google Scholar
  68. 68.
    Tollefson, G. Neuropsychiatric sequelae and cephalothin (letter). J. Clin. Psychiat. 45 (1984) 96.Google Scholar
  69. 69.
    Schweitzer, V. G., Olson, N. R. Ototoxic effects of erythromycin therapy. Arch. Otolaryngol. Head Neck Surg. 110 (1984) 258–260.Google Scholar
  70. 70.
    Umstead, G. S., Neumann, K. H. Erythromycin ototoxicity and acute psychotic reaction in cancer patients with hepatic dysfunction. Arch. Intern. Med. 146 (1986) 897–899.Google Scholar
  71. 71.
    Cohen, I. J., Weitz, R. Psychiatric complications with erythromycin. Drug Intell. Clin. Pharm. 15 (1981) 388.Google Scholar
  72. 72.
    Wadlington, W. B., Hatcher, H., Turner, D. J. Osteomyelitis of the patella: Gentamycin therapy associated with encephalopathy. Clin. Pediatr. 10 (1971) 577–580.Google Scholar
  73. 73.
    Kane, F. J., Byrd, G. Case report. Acute toxic psychosis associated with gentamicin therapy. South Med. J. 68 (1975) 1283–1285.Google Scholar
  74. 74.
    Byrd, G. Acute organic brain syndrome associated with gentamicin therapy. J. Amer. Med. Assoc. 238 (1977) 53–54.Google Scholar
  75. 75.
    Finegold, S. M. Toxicity of kanamycin in adults. Ann. NY Acad. Sci. 132 (1966) 942–956.Google Scholar
  76. 76.
    Kusumi, R. K., Plouffe, J. F., Wyatt, R. H., Fass, R. J. Central nervous system toxicity associated with metronidazole therapy. Ann. Intern. Med. 93 (1980) 59–60.Google Scholar
  77. 77.
    Frytak, S., Moertel, C. H., Childs, D. S., Albers, J. W. Neurologic toxicity associated with high-dose metronidazole therapy. Ann. Intern. Med. 88 (1978) 361–362.Google Scholar
  78. 78.
    Scharer, K. Sekektive Purkinje-Zellschädigung nach oraler Verabreichung großer Dosen von Nitroimidazol-Derivaten am Hund. Dtsch. Ges. Pathol. 56 (1972) 407–410.Google Scholar
  79. 79.
    Wood, J. D., Peesker, S. J. The effect on GABA metabolism in brain of isonicotinic acid hydrazide and pyridoxine as a function of timer after administration. J. Neurochem. 19 (1972) 1527–1537.Google Scholar
  80. 80.
    Torning, K., Olsen, P. Z. Isoniazid and impairment of memory. Dis. Chest 53 (1968) 675–678.Google Scholar
  81. 81.
    Reilly, D. K. Isoniazid related CNS-toxicity. Drug. Ther. 9 (1979) 187–188.Google Scholar
  82. 82.
    Devadatta, S. Isoniazid-induced encephalopathy. Lancet ii (1965) 440.Google Scholar
  83. 83.
    Reilly, R. H., Killam, K. F., Jenney, E. H., Marshal, W. H., Tausig, T., Apter, N. S. Convulsant effects of isoniazid. J. Amer. Med. Assoc. 152 (1953) 1317–1321.Google Scholar
  84. 84.
    Brown, C. V. Acute isoniazid poisoning. Am. Rev. Respir. Dis. 105 (1972) 206–216.Google Scholar
  85. 85.
    Whitefield, C. L., Cline, R. G. Isoniazid overdose: report of 40 patients with a critical analysis of treatment and suggestions of prevention. Am. Rev. Respir. Dis. 103 (1971) 887.Google Scholar
  86. 86.
    Sievers, M. L., Herrier, R. N. Treatment of acute isoniazid toxicity. Am. J. Hosp. Pharm. 32 (1975) 202–206.Google Scholar
  87. 87.
    Lehr, D. Clinical toxicity of the sulfonamides. Ann. NY Acad. Sci. 69 (1957) 417–447.Google Scholar

Copyright information

© MMV Medizin Verlag GmbH München 1991

Authors and Affiliations

  • G. Stoppe
    • 1
  • E. Rüther
    • 1
  1. 1.Psychiatrische Klinik, Universität GöttingenGöttingenGermany

Personalised recommendations